Esophageal Squamous Cell Carcinoma Clinical Trials in Chicago, Illinois

3 studies are recruiting for esophageal squamous cell carcinoma in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

    Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors. ABBV-400 is an investigational drug being…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Northwestern University Feinberg School of Medicine /ID# 257378, Chicago, Illinois
    Locations
    54 in total
    Run by
    AbbVie

    See if you can join NCT06084481 on ClinicalTrials.gov

  2. A Study of Sigvotatug Vedotin in Advanced Solid Tumors

    This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A side effect is anything the drug …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    UChicago Medicine - River East, Chicago, Illinois
    Locations
    158 in total
    Run by
    Seagen, a wholly owned subsidiary of Pfizer

    See if you can join NCT04389632 on ClinicalTrials.gov

  3. A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P02 monotherapy in adult patients with selected squamous solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    The University of Chicago Medical Center - Oncology, Chicago, Illinois
    Locations
    41 in total
    Run by
    Alentis Therapeutics AG

    See if you can join NCT06747585 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.